Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07819214) titled 'Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: University of California, Irvine
Condition:
CLL
CLL (Chronic Lymphocytic Leukemia)
Chronic Lymphocytic Leukemia (CLL)
BTKi
Intervention:
Drug: Epcoritamab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 24
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials...